Keros Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Keros Therapeutics has a total shareholder equity of $420.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $455.0M and $34.1M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$405.86m
Equity	US$420.92m
Total liabilities	US$34.11m
Total assets	US$455.02m

Recent financial health updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27

Keros Therapeutics prices equity offering at $50

Nov 13

Financial Position Analysis

Short Term Liabilities: KROS's short term assets ($432.7M) exceed its short term liabilities ($21.2M).

Long Term Liabilities: KROS's short term assets ($432.7M) exceed its long term liabilities ($12.9M).

Debt to Equity History and Analysis

Debt Level: KROS is debt free.

Reducing Debt: KROS has no debt compared to 5 years ago when its debt to equity ratio was 54.9%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KROS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KROS has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 40.7% each year.

Keros Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Recent updates

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$158k worth of stock

Chief Scientific Officer exercised options and sold US$133k worth of stock

Keros Therapeutics, Inc. Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Chief Scientific Officer exercised options and sold US$527k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Consultant Claudia Ordonez has left the company

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Microcap Value Index

Keros Therapeutics, Inc. Announces Preliminary Results from Its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

Chief Scientific Officer notifies of intention to sell stock

Keros Therapeutics, Inc. Presents Data from the ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of KER-012

Chief Scientific Officer exercised options and sold US$132k worth of stock

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$316k worth of stock

Chief Scientific Officer exercised options and sold US$340k worth of stock

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Keros Therapeutics, Inc. Announces Results from Preclinical Studies of KER-050 and ALK2 Inhibitor Program

New 90-day low: US$55.25

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Keros Therapeutics, Inc. Announces Board Changes

New 90-day high: US$79.96